4-[(2Z)-2-(5-oxo-1,3-diphenylpyrazol-4-ylidene)hydrazinyl]benzenesulfonic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(2Z)-2-(5-oxo-1,3-diphenylpyrazol-4-ylidene)hydrazinyl]benzenesulfonic acid
• 化学式: C₂₁H₁₆N₄O₄S
• 分子量: 420.4
• InChiKey: AHIATZZLZYGMTB-ATJXCDBQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases
  申请人：MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN

  公开号：EP1728790A1

  公开（公告）日：2006-12-06

  The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns a method for treating a proliferative disease, a genetic disorder, an autoimmune disease, an angiogenic disorder or cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I) and/or (II).

  本发明涉及小分子蛋白酪氨酸磷酸酶抑制剂，特别是Shp-2抑制剂，其化学式为(I)或(II)，以及包含它们的制药组合物。本发明还涉及使用所述化合物治疗磷酸酶介导的疾病，特别是癌症和转移的用途。本发明进一步涉及一种用于治疗患有增殖性疾病、遗传性疾病、自身免疫性疾病、血管生成性疾病或癌症的患者的方法，包括向该患者施用至少一种化合物(I)和/或(II)的治疗有效量。
• Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases
  申请人：Hellmuth Klaus

  公开号：US20080194563A1

  公开（公告）日：2008-08-14

  The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns a method for treating a proliferative disease, a genetic disorder, an autoimmune disease, an angiogenic disorder or cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I) and/or (II).

  本发明涉及小分子蛋白酪氨酸磷酸酶抑制剂，特别是Shp-2抑制剂，其化学式为(I)和/或(II)，以及包含它们的制药组合物。该发明还涉及使用所述化合物治疗磷酸酶介导的疾病，特别是癌症和转移。本发明还涉及一种治疗增殖性疾病、遗传性疾病、自身免疫性疾病、血管生成障碍或癌症的方法，包括向该患者施用至少一种化合物(I)和/或(II)的治疗有效量。
• SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES
  申请人：MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN

  公开号：EP1885717B1

  公开（公告）日：2011-08-17
• US7868185B2
  申请人：——

  公开号：US7868185B2

  公开（公告）日：2011-01-11
• [EN] SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES<br/>[FR] INHIBITEURS DE SHP-2, COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT ET UTILISATION DE CES DERNIERES DANS LE TRAITEMENT DES MALADIES MEDIEES PAR LA PHOSPHATASE
  申请人：MAX DELBRUECK CENTRUM

  公开号：WO2006128909A1

  公开（公告）日：2006-12-07

  [EN] The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns a method for treating a proliferative disease, a genetic disorder, an autoimmune disease, an angiogenic disorder or cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I) and/or (II).
  [FR] La présente invention concerne des inhibiteurs de la protéine à petites molécules tyrosine phosphatase, en particulier des inhibiteurs de Shp-2, de la formule (I) et/ou (II), et des compositions pharmaceutiques renfermant ces derniers. L'invention porte également sur l'utilisation desdits composés dans le traitement des maladies médiées par la phosphatase, en particulier le cancer et les métastases. L'invention se rapporte en outre à un procédé permettant de traiter une maladie proliférative, une affection génétique, une maladie auto-immune, un trouble angiogénique ou un cancer chez un patient qui a besoin d'un tel traitement, lequel procédé consiste à administrer au patient une quantité thérapeutiquement efficace d'au moins un composé de la formule (I) et/ou de la formule (II).